Family Capital Management Inc. Invests $742,000 in Pfizer Inc. $PFE

Family Capital Management Inc. acquired a new position in Pfizer Inc. (NYSE:PFE) during the second quarter, HoldingsChannel.com reports. The fund acquired 30,610 shares of the biopharmaceutical company’s stock, valued at approximately $742,000.

Other institutional investors have also made changes to their positions in the company. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer in the first quarter worth $27,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer in the first quarter worth $28,000. North Capital Inc. bought a new stake in shares of Pfizer in the first quarter worth $28,000. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer in the second quarter worth $29,000. Finally, WPG Advisers LLC bought a new stake in shares of Pfizer in the first quarter worth $35,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE:PFE opened at $24.84 on Wednesday. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.17. The company has a market cap of $141.23 billion, a P/E ratio of 13.21, a P/E/G ratio of 0.82 and a beta of 0.55. The firm’s fifty day moving average price is $24.89 and its two-hundred day moving average price is $24.13. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the company earned $0.60 earnings per share. The company’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on PFE shares. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Bank of America boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Finally, Morgan Stanley lowered their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.